LumiraDx Limited (LMDX)
Company Description
LumiraDx is a next-generation point of care, or POC, diagnostic company. We have developed and launched our LumiraDx Platform, or Platform, which is an integrated system comprised of a small, versatile POC instrument, or Instrument, precise, low-cost microfluidic test strips, and seamless, secure digital connectivity.
We currently have four tests available on our Platform and a broad menu of tests in development. Our proprietary Platform is designed to simplify, scale down, and integrate multiple testing methodologies onto a single instrument and offer a broad menu of tests with lab-comparable performance at a low cost and with results generally in 10 minutes or less from sample to result.
Our goal is to address the key challenges faced by healthcare providers in providing efficient and cost-effective patient care in a community setting.
In response to the COVID-19 pandemic and the resulting acute need for timely diagnostic information, we have developed our SARS-CoV-2 antigen and SARS-CoV-2 antibody tests for use in community-based healthcare settings.
As of December 31, 2020, we have placed more than 7,000 Instruments with over 500 customers across more than 25 countries and have more than 1,000 staff across the globe.
| Country | United States |
| Founded | 2014 |
| Industry | Diagnostics & Research |
| Sector | Health Care |
| Employees | 1,022 |
| CEO | Ron Zwanziger |
Contact Details
Address: 221 Crescent Street. 5th Floor Waltham, MA 02453 United States | |
| Phone | 44 11 7284 2535 |
| Website | lumiradx.com |
Stock Details
| Ticker Symbol | LMDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 1685428 |
Key Executives
| Name | Position |
|---|---|
| Ron Zwanziger | Chief Executive Officer, Co-Founder and Chairman |
| Dr. David Scott Ph.D. | Chief Technology Officer, Co-Founder and Director |
| Dr. Jerome F. McAleer | Chief Scientist, Co-Founder and Director |
| Dorian LeBlanc CPA | Chief Financial Officer and Vice President of Global Operations |
| Veronique Ameye | Executive Vice President and General Counsel |
| Colleen McMillen | Vice President of Communications |
| Andy Ward | National Sales Director - UK |
| Peter Scheu | President of North American Commercial Operations |
| David Walton | Chief Commercial Officer |
| Dr. Nigel Lindner | Chief Innovation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 11, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| May 2, 2022 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 2, 2022 | F-1 | Registration statement for certain foreign private issuers |
| Apr 27, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Apr 13, 2022 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] |
| Mar 10, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Mar 9, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Mar 3, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| Mar 1, 2022 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] |
| View All SEC Filings | ||